CoChat

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study

Open access
Boye, Kristina, Ross, Melissa, Mody, Reema, Konig, Manige, Gelhorn, Heather · 2021 · Diabetes, Obesity and Metabolism
Cited by 88

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aims: To understand patient preferences for once‐daily oral versus once‐weekly injectable type 2 diabetes mellitus (T2DM) medication administration profiles, and reasons for their preferences. Materials and methods: The REVISE study, a cross‐sectional online survey of 600 participants with T2DM (United Kingdom, n = 300; United States, n = 300), elicited general preferences for once‐daily oral versus once‐weekly injectable diabetes medications, and reasons for the preference. Participants then viewed two videos describing the administration procedures for injectable dulaglutide and oral semaglutide, based on the product instructions for use. Thereafter, participants indicated their preference for a once‐weekly injectable or a once‐daily oral medication based on the video descriptions. Participants who switched preferences were asked to identify the reasons influencing their decision. Results: The participants were predominantly male (n = 349; 58.2%), with a mean (SD) age of 64 (11.3) years. Nearly all (n = 557; 92.8%) were taking an oral T2DM medication, and 158 (26.3%) were using an injectable. Initially, 76.5% (n = 459; 95% confidence interval [CI] 73.1–79.9) preferred a once‐daily oral and 23.5% a once‐weekly injectable (n = 141; 95% CI 20.1–26.9; P < 0.0001). After viewing the videos describing the product‐specific administration, the proportions of participants preferring each option were not statistically different (oral semaglutide administration description (n = 315; 52.5%; 95% CI 48.5–56.5; dulaglutide administration description (n = 285; 47.5%; 95% CI 43.5–51.5; NS, P = 0.2207). The most common reason for switching preferences was the timing and steps of administration. Conclusion: Several treatment‐related characteristics, including route, frequency and complexity of the treatment, play a role in patients' preferences for T2DM treatments and should be considered during treatment selection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14244

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 10

  1. 10.1016/j.jval.2019.11.009 · doi:10.1016/j.jval.2019.11.009
  2. 10.1185/03007995.2011.625404 · DOI
  3. 10.1177/0145721706288182 · DOI
  4. 10.1007/s40271-017-0225-0 · DOI
  5. 10.1185/03007995.2015.1117433 · DOI · Paper page
  6. 10.1177/2042018815595584 · DOI
  7. 10.2147/PPA.S14477 · DOI · Paper page
  8. 10.1186/s12913-015-1174-8 · DOI · Paper page
  9. 10.1016/j.clinthera.2016.05.009 · DOI · Paper page
  10. 10.1007/s40258-013-0023-3 · DOI · Paper page

Cited by

See all 88

Metadata

Authors
Boye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2020-12-13
Volume
23
Issue
2
Pages
508-519
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3095909321
Cited by
88
References
5
FWCI
5.41
Type
journal article
Language
en
Open access
hybrid
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.